These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 17671144

  • 1. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations.
    Kiyoi H, Shiotsu Y, Ozeki K, Yamaji S, Kosugi H, Umehara H, Shimizu M, Arai H, Ishii K, Akinaga S, Naoe T.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4575-82. PubMed ID: 17671144
    [Abstract] [Full Text] [Related]

  • 2. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.
    J Natl Cancer Inst; 2008 Feb 06; 100(3):184-98. PubMed ID: 18230792
    [Abstract] [Full Text] [Related]

  • 3. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A, Kiyoi H, Towatari M, Naoe T.
    Leukemia; 2007 Mar 06; 21(3):403-10. PubMed ID: 17230226
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity of sorafenib in FLT3-driven leukemic cells.
    Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, Zhang X, Wilkie D, Burd A, Shi H, Rocks S, Gedrich R, Abriola L, Vasavada H, Lynch M, Dumas J, Trail PA, Wilhelm SM.
    Leukemia; 2007 Mar 06; 21(3):439-45. PubMed ID: 17205056
    [Abstract] [Full Text] [Related]

  • 5. Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations.
    Nishiyama U, Yoshino T, Ozai M, Yoshioka R, Fujisawa M, Ogasawara Y, Kitahori M, Yoshioka E, Kubo K, Komeno Y, Kurokawa M, Ogawa S, Chiba S, Osawa T, Kuwaki T, Hirai H, Miwa A.
    Leuk Res; 2006 Dec 06; 30(12):1541-6. PubMed ID: 16603240
    [Abstract] [Full Text] [Related]

  • 6. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y, Shephard L, Goldbeck C, Oei Y, Ye H, Aukerman SL, Heise C.
    Clin Cancer Res; 2005 Jul 15; 11(14):5281-91. PubMed ID: 16033847
    [Abstract] [Full Text] [Related]

  • 7. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
    Nishioka C, Ikezoe T, Yang J, Takeuchi S, Koeffler HP, Yokoyama A.
    Leuk Res; 2008 Sep 15; 32(9):1382-92. PubMed ID: 18394702
    [Abstract] [Full Text] [Related]

  • 8. FLT3/ ITD regulates leukaemia cell adhesion through α4β1 integrin and Pyk2 signalling.
    Katsumi A, Kiyoi H, Abe A, Tanizaki R, Iwasaki T, Kobayashi M, Matsushita T, Kaibuchi K, Senga T, Kojima T, Kohno T, Hamaguchi M, Naoe T.
    Eur J Haematol; 2011 Mar 15; 86(3):191-8. PubMed ID: 21114537
    [Abstract] [Full Text] [Related]

  • 9. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.
    Dtsch Med Wochenschr; 2002 Oct 18; 127(42):2195-200. PubMed ID: 12397548
    [Abstract] [Full Text] [Related]

  • 10. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation.
    Agrawal S, Koschmieder S, Bäumer N, Reddy NG, Berdel WE, Müller-Tidow C, Serve H.
    Leukemia; 2008 Jan 18; 22(1):78-86. PubMed ID: 17943165
    [Abstract] [Full Text] [Related]

  • 11. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.
    Exp Hematol; 2010 Aug 18; 38(8):641-52. PubMed ID: 20380868
    [Abstract] [Full Text] [Related]

  • 12. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW, Wang AN, Liao HA, Chen CY, Hou HA, Hu CY, Tien HF, Ou DL, Lin LI.
    Cancer Lett; 2016 Jul 01; 376(2):218-25. PubMed ID: 27060207
    [Abstract] [Full Text] [Related]

  • 13. Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1.
    Yoshida A, Ookura M, Zokumasu K, Ueda T.
    Biochem Pharmacol; 2014 Jul 01; 90(1):16-24. PubMed ID: 24735609
    [Abstract] [Full Text] [Related]

  • 14. Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia.
    Eriksson A, Höglund M, Lindhagen E, Aleskog A, Hassan SB, Ekholm C, Fhölenhag K, Jensen AJ, Löthgren A, Scobie M, Larsson R, Parrow V.
    Biochem Pharmacol; 2010 Nov 15; 80(10):1507-16. PubMed ID: 20705060
    [Abstract] [Full Text] [Related]

  • 15. ITD- and FL-induced FLT3 signal transduction leads to increased C/EBPbeta-LIP expression and LIP/LAP ratio by different signalling modules.
    Haas SC, Huber R, Gutsch R, Kandemir JD, Cappello C, Krauter J, Duyster J, Ganser A, Brand K.
    Br J Haematol; 2010 Mar 15; 148(5):777-90. PubMed ID: 19958352
    [Abstract] [Full Text] [Related]

  • 16. Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.
    Skwarska A, Augustin E, Beffinger M, Wojtczyk A, Konicz S, Laskowska K, Polewska J.
    Biochem Pharmacol; 2015 Jun 15; 95(4):238-52. PubMed ID: 25896848
    [Abstract] [Full Text] [Related]

  • 17. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells.
    Chen F, Ishikawa Y, Akashi A, Naoe T, Kiyoi H.
    Oncotarget; 2016 Jul 26; 7(30):47018-47032. PubMed ID: 27331411
    [Abstract] [Full Text] [Related]

  • 18. The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia.
    Kasper S, Breitenbuecher F, Hoehn Y, Heidel F, Lipka DB, Markova B, Huber C, Kindler T, Fischer T.
    Leuk Res; 2008 Nov 26; 32(11):1698-708. PubMed ID: 18556063
    [Abstract] [Full Text] [Related]

  • 19. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
    Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A.
    Leukemia; 2007 Aug 26; 21(8):1658-68. PubMed ID: 17541402
    [Abstract] [Full Text] [Related]

  • 20. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.
    Jin G, Matsushita H, Asai S, Tsukamoto H, Ono R, Nosaka T, Yahata T, Takahashi S, Miyachi H.
    Biochem Biophys Res Commun; 2009 Dec 18; 390(3):1001-6. PubMed ID: 19853583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.